TIDMD467
Thames Ventures VCT 2 plc
LEI: 21380035MV1VRYEXPR95
Half Yearly Results
22 December 2022
Financial Highlights
Unaudited Audited Unaudited
30 31 30
September March September
2022 2022 2021
pence pence pence
Ventures Share pool
--------------------------------------------- ---------- ------- ----------
Net Asset Value per Ventures Share 68.50 68.20 68.50
--------------------------------------------- ---------- ------- ----------
Cumulative distributions 8.00 5.25 5.25
--------------------------------------------- ---------- ------- ----------
Total Return per Ventures Share 76.50 73.45 73.75
--------------------------------------------- ---------- ------- ----------
Healthcare Share pool
--------------------------------------------- ---------- ------- ----------
Net Asset Value per Healthcare Share 71.70 84.40 88.70
--------------------------------------------- ---------- ------- ----------
Cumulative distributions 8.75 5.25 5.25
--------------------------------------------- ---------- ------- ----------
Total Return per Healthcare Share 80.45 89.65 93.95
--------------------------------------------- ---------- ------- ----------
AIM Share pool
--------------------------------------------- ---------- ------- ----------
Net Asset Value per AIM Share 99.0 99.9 n/a
--------------------------------------------- ---------- ------- ----------
Cumulative distributions - - n/a
--------------------------------------------- ---------- ------- ----------
Total Return per AIM Share 99.0 99.9 n/a
--------------------------------------------- ---------- ------- ----------
DSO D Share pool
--------------------------------------------- ---------- ------- ----------
Net Asset Value per DSO D Share 2.6 2.6 10.2
--------------------------------------------- ---------- ------- ----------
Cumulative distributions 102.0 102.0 94.5
--------------------------------------------- ---------- ------- ----------
Adjusted for Performance Incentive estimate - - (0.3)
--------------------------------------------- ---------- ------- ----------
Total Return per DSO D Share 104.6 104.6 104.4
--------------------------------------------- ---------- ------- ----------
DP67 Share pool
--------------------------------------------- ---------- ------- ----------
Net Asset Value per DP67 Share 24.4 26.8 19.5
--------------------------------------------- ---------- ------- ----------
Cumulative distributions (since original
launch) 67.8 67.8 67.8
--------------------------------------------- ---------- ------- ----------
Total Return per DP67 Share 92.2 94.6 87.3
--------------------------------------------- ---------- ------- ----------
Chairman's Statement
Introduction
I am pleased to present the Company's Half-Yearly Report for the
six months ended 30 September 2022.
During the period the Company has seen a change of Investment
Manager and a change of name. In terms of investments,
macro-economic conditions are increasingly challenging, which have
contributed to some mixed results over the period for the existing
portfolio companies.
Investment Management Arrangements and Change of name
As set out to you in the Annual Report, Foresight Group LLP
("Foresight") purchased the non-healthcare ventures division of
Downing LLP in July 2022, and the Board consented for the
investment management agreement to be novated to Foresight.
The management of the Healthcare Share pool remains with Downing
LLP, who are also continuing to provide investment management
services for the planned exit and AIM share pools alongside the
administration services for the VCT as a whole.
On 2 September 2022 the Company changed its name to Thames
Ventures VCT 2 plc to recognise the change in main Investment
Manager.
Fundraising
After the period end, in October 2022, the Company launched a
new offer for subscription for the Healthcare Share class, closely
followed, in early November, by an offer for the Ventures Share
class, seeking to raise up to GBP10 million in each class, with an
overallotment facility of up to GBP10 million respectively.
The Board believes that the Company offers an attractive
proposition for VCT investors, as both the Ventures and Healthcare
Share pools are still relatively young although the earliest
investments are now several years old and making progress towards
maturing.
Full details of the offer can be found on the Foresight and
Downing websites:
Ventures:
https://www.globenewswire.com/Tracker?data=CIql0mi254ugy5hovT8VULnGqza6GtXZIB5CUfWwBYPScysp3eYEhWkL3wQnNnHsGNkqASAKu_sNatlSC7XgEdZfsvG3VrNWmkw_Hqa0a0-ibTVwujf2mE_Im9He8trU_0-baTVjQHsYJD1WBmwZ3oa7bC1E-Z1aVbKMlRW-mWk2HtpBvUUyF_S-JQVJiqY7wFjfFbdtSoZz0j0QqVoetQ==
www.foresightgroup.eu/products/thames-ventures-vct-2-plc
Healthcare:
https://www.globenewswire.com/Tracker?data=CIql0mi254ugy5hovT8VUJ5c5Sry9r1fmBkryd4EOhxr4BXPkA0-yKnbK6w1uSoQ6AYcWpGpKxeWg3yB9mfc-pmq0Kpf-Eb7mXtCTQGxuOiDXKnH_qODOvlu48ibw7sejyYIP2hgtii70JiZPmu63A==
www.downing.co.uk/investor/products/vct
Evergreen Share pool review
Ventures Share pool
During the period, the Ventures Share pool made a number of new
and follow-on investments totalling GBP3.5 million, as well as
completing three full exits generating a total of GBP4.1 million
proceeds. The Ventures Share class Total Return stood at 76.5p as
at 30 September 2022. This is an increase of 3.0p or 4.5% in NAV
over the period, after adjusting for the dividend of 2.75p per
Ventures Share, paid on 30 September 2022.
The Net Asset Value per share ("NAV") increase over the period
results from several valuation uplifts within the portfolio,
including Hackajob Limited and Cornelis Networks, Inc., which along
with the other US Dollar denominated investments, had also
benefitted significantly from the US Dollar strengthening against
Sterling, although some of those gains have reversed since the
period end, as Sterling has recovered some ground.
There was a final redemption from MI Downing UK Micro-Cap Growth
Fund during the period, which has now returned all its funds as
part of its wind up. The investment in Downing Strategic Micro-Cap
Investment Trust plc fell in value during the period, broadly in
line with the trend for small cap stocks.
A more detailed review of the Ventures Share pool is included in
the Ventures Investment Manager's.
Healthcare Share pool
The Healthcare Share pool continues to be managed by Downing
LLP, who have a dedicated and enlarged Healthcare investment
management team. During the period, the Healthcare Share pool made
one follow-on investment of GBP805,000 in FVRVS Limited (trading as
Fundamental VR), including the conversion of a loan note already
held in the company. Proceeds of GBP842,000 were generated on two
other exits completed in the period, discussed in more detail in
the Investment Manager's Report.
As at 30 September 2022, the Healthcare Share pool Total Return
stood at 80.45p. This is a decrease of 9.2p or 10.9% on NAV over
the period, after adjusting for the dividend of 3.5p per Healthcare
Share, paid on 30 September 2022.
The NAV decrease over the period is largely attributable to the
fall in the valuation of the two companies which floated on AIM in
2021: Arecor and GENinCode. Based on their quoted share prices as
at 30 September 2022, Arecor and GENinCode showed unrealised
valuation losses totalling GBP1.8 million for the period. Share
market liquidity for both businesses is limited, amplifying the AIM
market share price falls and volatility as the general economic
climate deteriorates. The remaining investments in the Healthcare
ventures portfolio showed unrealised losses of GBP100,000 for the
period.
As with the Ventures Share pool, the Healthcare Share pool
received a final redemption from MI Downing UK Micro-Cap Growth
Fund, which has now wound up.
A more detailed review of the Healthcare Share pool is included
in the Investment Manager's Report on pages 9 to 11.
AIM Share pool
As part of the change in management arrangements, Downing has
agreed to provide management services in respect of the AIM Share
pool for an interim period.
The deal flow for VCT qualifying AIM raises has been
disappointing as IPOs have dried up and market sentiment has not
supported new fundraises, against a backdrop of deteriorating
general economic conditions. However, the Manager continues to see
all new qualifying secondary and imminent IPOs and is using this
time to do enhanced due diligence on potential investments. Since
the period end, funds have been invested in liquidity assets which
include a yielding money market fund and a market tracker.
Planned Exit Share pools
As with the AIM Share pool, Downing LLP continues to provide
investment management services in respect of the investments held
by the planned exit share pools.
DSO D Share pool
The DSO D Share pool continues to hold the two remaining
investments. At the period end, NAV stood at 2.6p. Total Return at
30 September 2022 stood at 104.6p per share, unchanged since 31
March 2022.
The Manager is finalising plans to exit from these two
businesses with exposure to the hospitality sector, Pearce and
Saunders Limited and Pearce and Saunders DevCo Limited. It is
expected that these two investments will exit by Q2 2023.
A more detailed review of the DSO D Share pool is included in
the Investment Manager's Report on page 12.
DP67 Share pool
The DP67 Share pool continues to hold three remaining
investments of value. At the period end, NAV stood at 24.4p. Total
Return at 30 September 2022 stood at 92.2p per share, a decrease of
2.4p per share since 31 March 2022.
The DP67 Share pool has significant exposure to the hospitality
sector and progress continues to be slow in the aftermath of the
pandemic. However, the Manager is hopeful that it will be able to
secure the remaining exits in the early months of 2023.
A more detailed review of the DP67 Share pool is included in the
Investment Manager's Report on page 14.
Dividends
On 30 September 2022, the Company paid dividends in respect of
the year ended 31 March 2022 of 2.75p per Ventures Share and 3.5p
per Healthcare Share. This brings the total dividends paid to date
on each of the Ventures and Healthcare Share pools, to 8.0p and
8.75p respectively.
Dividends in respect of the Ventures and Healthcare Share
classes are paid once a year, typically in September. Both share
classes target a dividend level of at least 4% of NAV per
annum.
For both the DSO D and DP67 Share pools, the next and final
dividends will be declared once further realisations have taken
place.
The AIM Share class has no target dividend and is unlikely to
pay any dividend in these early years of its life.
Share buybacks
The Company operates a general policy of buying in shares from
its Evergreen Share pools (Ventures, Healthcare and AIM) that
become available in the market, subject to regulatory and liquidity
factors. Any such purchases are undertaken at a price approximately
equal to NAV (i.e. at a nil discount).
As the planned exit share classes are in the process of
returning funds to Shareholders, the Company no longer operates a
share buyback policy in respect of the DSO D and DP67 Share
classes.
During the six-month period ended 30 September 2022, the Company
repurchased Ventures Shares and Healthcare Shares, at average
prices of 67.15p and 78.51p per share, respectively.
If you wish to sell or buy Shares in the Company, Panmure Gordon
can supply details of closed periods etc. Contact details can be
found on the Shareholder Information page of this Half-Yearly
Report. Shareholders are reminded that any sales of shares before
they have been held for five years from allotment will normally
result in the loss of the initial income tax relief.
Outlook
The Board is encouraged by the continuing deployment of funds in
building the Ventures Share portfolio, now under the management of
the team at Foresight. There remains some cash for investment in
this, and we hope to see new funds raised under the current offers
which will support the existing portfolio, allowing further
diversification as the Company takes advantage of new
opportunities.
For the planned exit share pools, the ongoing delays in exiting
the investments are frustrating, but we are now hopeful that these
can be brought to a close in the near future. The Board is
satisfied that the Manager's strategy in working towards exits
while seeking to achieve optimal values is sensible. We hope to
complete the task of returning final funds to these shareholders
within the next six months.
Although there are now significant challenges for businesses in
most sectors, the Board believes that young growth companies still
have the ability to offer attractive rewards to investors. Funds
raised under the offers for subscription will allow the Company to
take advantage of new such opportunities. The Board hopes to see
the ventures investment team leverage the full benefits of the
regional office network and other resources of the Foresight Group
and will be looking to both Managers to identify suitable new
potential investments to further diversify the portfolios, while
also closely monitoring and supporting the existing
investments.
I look forward to updating all Shareholders in my statement with
the Annual Report, which we expect to publish in July 2023.
Sir Aubrey Brocklebank Bt.
Chairman
Investment Manager's Report - Ventures Share Pool
Introduction
We are pleased to present our first review of the investment
portfolio for the Ventures Share pool as Foresight Group LLP,
following the acquisition by Foresight of Downing LLP's
non-healthcare ventures investment division in the summer.
This Investment Manager's Report is split into two sections
comprising this overview and a review of the portfolio. Where the
Ventures Share pool has invested alongside the Healthcare Share
pool, further valuation commentary can be found within the
Investment Manager's Report for the Healthcare Share pool, on pages
9 and 10.
Introduction to the Foresight Group
Foresight is a leading private equity and infrastructure
investment manager with its parent company, Foresight Group
Holdings Limited, listed on the London Stock Exchange. Established
in 1984, Foresight has a track record of over 35 years investing
into and growing small companies. The Foresight Group now has more
than GBP12.5 billion of assets under management and a wide and
varied investor base of private and institutional investors and has
a commitment to attracting and retaining high quality and
experienced staff.
We are pleased to report that the team that transferred from
Downing is now well settled and is recruiting in line with
expansion plans. They are also now starting to benefit from working
with other teams within Foresight to generate new deal flow.
Net Asset Value and results
As at 30 September 2022, the NAV of a Ventures Share stood at
68.5p, an increase of 3.0p from 31 March 2022, after adding back
the dividend of 2.75p which was paid during the period.
The return on ordinary activities for the Ventures Share pool
for the period was GBP1.7 million, comprising a revenue loss of
GBP228,000 and a capital gain of GBP1.9 million.
There continues to be further recovery in the NAV since 31 March
2022, with the Total Return to Shareholders as at 30 September 2022
being 76.5p per share.
Portfolio Overview
As at 30 September 2022, the Ventures Share pool held a
portfolio of 37 ventures investments and one liquidity investment,
with a total carrying value of GBP32.6 million.
Portfolio Performance
Overall, there were 11 valuation increases in the ventures
portfolio, totalling GBP4.6 million, which more than offset the ten
valuation reductions, totalling GBP2.5 million. The net valuation
increase across the ventures portfolio was therefore GBP2.1 million
as at 30 September 2022.
The carrying values of the liquidity investments have been
adjusted to reflect their quoted prices as at 30 September 2022.
This resulted in a valuation decrease of GBP618,000 for the
half-year period.
Investment activity
During the period, GBP2.8 million was invested in new companies,
as set out below. GBP676,000 was invested in four existing business
in the ventures portfolio, of which one included a conversion of
loan notes into equity.
New portfolio companies
Vivacity Labs Limited (GBP493,000) is a provider of AI-driven
traffic congestion monitoring solutions and insights.
Maestro Media Limited (GBP340,000) have developed an online
streaming platform in collaboration with the BBC, offering personal
and insightful lessons from leading creative talents.
Glisser Limited (GBP199,000) is an award-winning platform for
hosting both virtual and in-person events.
Follow-on portfolio companies
FVRVS Limited (trading as Fundamental VR) provides surgery
simulation software for enterprise clients and hospitals. A further
GBP527,000 was invested, including conversion of the loan note
already held.
Smaller follow-on investments were also made into Streethub
Limited (trading as Trouva) (GBP70,000), Upp Technologies Group
Limited (GBP59,000) and Channel Mum Limited (GBP20,000).
Exits
There were two full exits in the period, the first being the
success story of E-Fundamentals (Group) Limited, a Software as a
Service (SaaS) analytics company, which has developed and
commercialised a SaaS analytics tool, which was sold for total
proceeds of GBP3.6 million at a gain over cost of GBP2.1 million.
GBP1.7 million of the consideration was in shares in CommerceIQ,
Inc which provides e-commerce management tools for the organisation
of retail media, sales and operations.
On a more disappointing note, Streethub Limited (trading as
Trouva), an online marketplace for a curated range of homeware and
lifestyle products, exited in full for a loss of GBP1.1 million
against total cost.
As noted above, GBP125,000 of loan notes held in FVRVS Limited
were converted to shares alongside the further investment made in
the period.
Portfolio valuation
During the period, the ventures portfolio of the Ventures Share
pool increased in value by a total of GBP2.8 million, following a
number of positive developments.
Hackajob Limited, the owner of a marketplace platform for hiring
technical talent, has continued to progress well during the period,
with recurring revenues continuing to grow and continued strong
progress on fundraising. The valuation was uplifted by GBP1.4
million as a result.
Cornelis Networks, Inc. is a technology provider delivering
purpose-built high-performance fabrics for High Performance
Computing, Analytics and Artificial Intelligence to leading
commercial, scientific, academic, and government organizations. The
valuation was uplifted by GBP1.5 million as at 30 September 2022,
as they continue to build-out customer base, drive new product and
raise additional funding. GBP400,000 of the increase is due to the
positive impact of USD/Sterling FX movements in the period since
the year end.
Virtual Class Limited (trading as Third Space Learning) provides
online lessons from specialist maths tutors to support school
children. They have achieved significant growth in recent years,
with revenues tripling since 2020 and the value has been uplifted
by GBP775,000 to reflect this.
Ayar Labs, Inc., the developer of components for high
performance computing and data centre applications, was uplifted in
valuation by GBP522,000 as at 30 September 2022, including the
impact of foreign exchange.
FundingXchange Limited, an SME funding platform and B2B
technology provider which enables online lending, was subject to a
further valuation reduction of GBP510,000 as at 30 September 2022,
as revenue performance continues to be behind forecast.
Arecor Therapeutics plc floated in 2021 and so is valued at the
quoted bid price. This is down GBP352,000 since the year end -- see
page 9 for further commentary.
It is disappointing to report that Channel Mum Limited, and
Hummingbird Technologies Limited are no longer expected to recover,
with a total reduction in value of GBP561,000 to bring the values
to nil.
There are a number of smaller valuation movements which offset
one another for the half-year period, resulting in a net positive
movement of GBP70,000.
Liquidity investments
The Ventures Share pool holds a non-qualifying investment in
Downing Strategic Micro-Cap Investment Trust plc ("DSM"). This
decreased in value by GBP618,000 over the period, broadly in line
with market conditions, although has seen some recovery since the
period end.
Downing Micro-Cap Growth Fund, in which the share pool also had
a small holding, completed the task of returning funds to
shareholder as part of its wind up, producing a realised gain of
GBP23,000 in the period.
Outlook
The six months to 30 September 2022, during which we became
investment manager, has been against a backdrop of increasingly
challenging market conditions, with inflation and global interest
rates rising, having an inevitable impact on the portfolio.
Despite this environment, we are continuing to see improved
performance from the Ventures Share class, driven by a number of
valuation uplifts. Those portfolio companies that survived the
current economic turbulence may be better placed than beforehand,
due to tighter cost and cash management.
We are now expanding our team to enable us to take full
advantage of the opportunities the new fundraising will present.
Our role over the remainder of the year will focus on continued
support of the existing portfolio companies in the ventures
portfolio, as well as looking to add new investments to this
portfolio with the remaining proceeds from the last
fundraising.
Thames Ventures VCT Team
Foresight Group LLP
Review of Investments -- Ventures Share Pool
The following investments were held at 30 September 2022:
Cost Valuation
as at as at 30 Valuation
30 September September movement % of
2022 2022 in period portfolio
Portfolio of investments GBP'000 GBP'000 GBP'000
Hackajob Limited 784 2,885 1,362 7.7%
--------------------------------------------- ------------- ---------- ---------- ------------
Cornelis Networks, Inc. 1,402 2,850 1,480 7.6%
--------------------------------------------- ------------- ---------- ---------- ------------
Virtual Class Limited (Third Space
Learning) 1,053 2,591 775 6.9%
--------------------------------------------- ------------- ---------- ---------- ------------
Ayar Labs, Inc. 764 2,048 522 5.5%
--------------------------------------------- ------------- ---------- ---------- ------------
Rated People Limited 1,382 1,917 22 5.1%
--------------------------------------------- ------------- ---------- ---------- ------------
Imagen Limited 1,000 1,763 - 4.7%
--------------------------------------------- ------------- ---------- ---------- ------------
CommerceIQ, Inc. 1,749 1,749 - 4.7%
--------------------------------------------- ------------- ---------- ---------- ------------
Cambridge Touch Technologies Limited 959 1,376 7 3.7%
--------------------------------------------- ------------- ---------- ---------- ------------
Trinny London Limited 219 1,374 134 3.7%
--------------------------------------------- ------------- ---------- ---------- ------------
Ecstase Limited (t/a ADAY) 1,000 1,182 (75) 3.2%
--------------------------------------------- ------------- ---------- ---------- ------------
Upp Technologies Group Limited (previously
Volo Commerce) 1,077 1,136 59 3.0%
--------------------------------------------- ------------- ---------- ---------- ----------
Firefly Learning Limited 1,047 1,047 - 2.8%
--------------------------------------------- ------------- ---------- ---------- ------------
FVRVS Limited (t/a Fundamental VR) 777 904 18 2.4%
--------------------------------------------- ------------- ---------- ---------- ------------
Parsable, Inc. 766 839 128 2.2%
--------------------------------------------- ------------- ---------- ---------- ------------
Arecor Therapeutics plc^ 418 789 (352) 2.1%
--------------------------------------------- ------------- ---------- ---------- ------------
Limitless Technology Limited 757 786 (134) 2.1%
--------------------------------------------- ------------- ---------- ---------- ------------
Carbice Corporation 656 753 114 2.0%
--------------------------------------------- ------------- ---------- ---------- ------------
Masters of Pie Limited 667 667 - 1.8%
--------------------------------------------- ------------- ---------- ---------- ------------
Congenica Limited 734 605 (141) 1.6%
--------------------------------------------- ------------- ---------- ---------- ------------
Vivacity Labs Limited 493 493 - 1.3%
--------------------------------------------- ------------- ---------- ---------- ------------
Maverick Pubs (Holdings) Limited 1,000 490 40 1.3%
--------------------------------------------- ------------- ---------- ---------- ------------
Fenkle Street LLP* 301 348 (57) 0.9%
--------------------------------------------- ------------- ---------- ---------- ------------
Maestro Media Limited 340 340 - 0.9%
--------------------------------------------- ------------- ---------- ---------- ------------
MIP Diagnostics Limited 300 300 - 0.8%
--------------------------------------------- ------------- ---------- ---------- ------------
FundingXchange Limited 1,050 276 (510) 0.7%
--------------------------------------------- ------------- ---------- ---------- ------------
Distributed Limited 275 275 - 0.7%
--------------------------------------------- ------------- ---------- ---------- ------------
Bulbshare Limited 249 249 - 0.7%
--------------------------------------------- ------------- ---------- ---------- ------------
Glisser Limited 199 199 - 0.5%
--------------------------------------------- ------------- ---------- ---------- ------------
Destiny Pharma plc^ 500 108 (45) 0.3%
--------------------------------------------- ------------- ---------- ---------- ------------
Channel Mum Limited 757 - (311) 0.0%
--------------------------------------------- ------------- ---------- ---------- ------------
Hummingbird Technologies Limited 750 - (250) 0.0%
--------------------------------------------- ------------- ---------- ---------- ------------
Lignia Wood Company Limited 1,778 - - 0.0%
--------------------------------------------- ------------- ---------- ---------- ------------
Empiribox Holdings Limited 1,563 - - 0.0%
--------------------------------------------- ------------- ---------- ---------- ------------
Live Better With Limited 1,211 - - 0.0%
--------------------------------------------- ------------- ---------- ---------- ------------
Ormsborough Limited 900 - - 0.0%
--------------------------------------------- ------------- ---------- ---------- ------------
Lineten Limited 400 - - 0.0%
--------------------------------------------- ------------- ---------- ---------- ------------
London City Shopping Centre Limited* 30 - - 0.0%
--------------------------------------------- ------------- ---------- ---------- ------------
29,307 30,339 2,786 80.9%
--------------------------------------------- ------------- ---------- ---------- ------------
Liquidity investment
--------------------------------------------- ------------- ---------- ---------- ------------
Downing Strategic Micro-Cap Investment
Trust plc*^ 4,269 2,257 (618) 6.0%
--------------------------------------------- ------------- ---------- ---------- ----------
33,576 32,596 2,168 86.9%
--------------------------------------------- ------------- ---------- ---------- ------------
Cash at bank and in hand 4,910 13.1%
--------------------------------------------- ------------- ---------- ---------- ------------
Total investments 37,506 100.0%
--------------------------------------------- ------------- ---------- ---------- ------------
*non-qualifying investment
^listed and traded on the London Stock Exchange
Investment movements for the period ended 30 September 2022
Cost
Additions GBP'000
CommerceIQ, Inc. 1,749
------------------------------- -------
FVRVS Limited (t/a Fundamental
VR) 527
------------------------------- -------
Vivacity Labs Limited 493
------------------------------- -------
Maestro Media Limited 340
------------------------------- -------
Glisser Limited 199
------------------------------- -------
Streethub Limited (t/a Trouva) 70
------------------------------- -------
Upp Technology Group Limited 59
------------------------------- -------
Channel Mum Limited 20
------------------------------- -------
3,457
------------------------------- -------
Valuation Profit/(loss) Realised
Cost at 01/04/22 Proceeds vs. cost gain
Disposals GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
E- Fundamentals Limited 1,508 3,847 3,607 2,099 (240)
------------------------------- ------- ------------ -------- ------------- --------
Streethub Limited (t/a Trouva) 1,349 141 242 (1,107) 101
------------------------------- ------- ------------ -------- ------------- --------
FVRVS Limited (t/a Fundamental
VR) 125 125 125 - -
------------------------------- ------- ------------ -------- ------------- --------
Liquidity investments
------------------------------- ------- ------------ -------- ------------- --------
MI Downing UK Micro-Cap Growth
Fund* 123 116 139 16 23
------------------------------- ------- ------------ -------- ------------- --------
3,105 4,229 4,113 1,008 (116)
------------------------------- ------- ------------ -------- ------------- --------
*non-qualifying investment
Investment Manager's Report- Healthcare Share Pool
Introduction
We present a review of the investment portfolio and activity for
the Healthcare Share pool over the six-month period to 30 September
2022.
As noted earlier in this report, although Foresight Group is now
the primary Investment Manager for the Company, Downing LLP
continues to be the Investment Manager of the Healthcare Share
Pool.
Net Asset Value and results
As at 30 September 2022, the NAV of the Healthcare Shares stood
at 71.7p, a decrease of 9.2p from 31 March 2022, after adding back
the dividend of 3.50p which was paid during the period. The vast
majority of this fall was from the quoted investments in the
portfolio.
The loss on ordinary activities for the Healthcare Share pool
for the period was GBP2.1 million, comprising a revenue loss of
GBP147,000 and a capital loss of GBP1.9 million.
The Total Return to Healthcare Shareholders, as at 30 September
2022, was 80.45p.
Portfolio Overview
As at 30 September 2022, the Healthcare Share pool held a
portfolio of 14 ventures investments and one liquidity investment,
with a combined value of GBP13.8 million.
The valuation movements during the period are discussed in more
detail in the following sections of this Investment Manager's
Report.
Portfolio Performance
There were a number of valuation movements in the Healthcare
ventures portfolio during the period, resulting in a net valuation
decrease of GBP1.9 million.
The carrying value of the liquidity investment has been adjusted
to reflect the quoted prices as at 30 September 2022. This resulted
in a valuation decrease of GBP106,000 for the period.
Investment activity
During the period, GBP805,000 was invested in FVRVS Limited
(trading as Fundamental VR) an existing portfolio company which
provides surgery simulation software for enterprise clients and
hospitals. Included in the investment was the conversion of a loan
note already held.
Exits
Future Health Works (trading as MyRecovery) was exited in full
during the period, generating proceeds of GBP798,000, being a
GBP270,000 gain over cost and a positive result for the
portfolio.
As noted above, GBP250,000 of loan notes held in FVRVS Limited
were converted to shares alongside the further investment made in
the period.
Final proceeds of GBP44,000 were also received from the wind up
of the MI Downing UK Micro-Cap Growth Fund.
Portfolio valuation
There were a number of valuation movements within the portfolio
over the period.
Arecor plc is quoted on AIM and valued at the bid price at 30
September 2022 of GBP2.40. The Healthcare Share pool's investment
saw a decrease in value of GBP1.3 million over the period. Despite
the fall in its quoted share price, the company is making headway,
having completed the acquisition of Tetris Pharma which has
launched a new diabetes treatment "Ogluo" in Germany. The company
itself has also made significant progress with its proprietary
portfolio and clinical trials are accelerating around their product
of ultra-concentrated rapid acting insulin. Despite a regular
positive news flow, the company's share price has dropped off. This
appears to be a combination of less market interest in low
liquidity, pre-revenue stocks and early investors selling into this
low liquidity market.
Genincode plc is also valued at its quoted bid price of 17p,
which has resulted in a reduction in value of GBP542,000 at 30
September 2022. The business has continued to underperform against
its targets; we continue to wait for meaningful US regulatory and
market access progress.
Congenica Limited has also underperformed against plan and,
accordingly, the value has been reduced by GBP350,000.
On a more positive note, Open Bionics Limited, an award-winning
designer, manufacturer and supplier of bionic limbs, has been
uplifted in value to calibrate to a recent funding round. The
company continues to exceed revenue budgets and meet its KPIs. The
resulting uplift for the Healthcare Share pool was GBP251,000 as at
30 September 2022.
DiA Imaging Analysis Limited ("DiA") was increased in value by
GBP139,000 as at 30 September 2022, to reflect an offer to acquire
the company, which is being explored further, along with the
movement in the exchange rate in the US Dollar/Sterling exchange
rate, since the last year end.
The valuation of FVRVS Limited (trading as Fundamental VR) has
been increased as a result of a calibration to the most recent
funding round. The valuation uplift for the Healthcare Share pool
was GBP36,000 as at 30 September 2022.
Destiny Pharma plc, which is listed on AIM, was reduced in value
by GBP67,000 as at 30 September 2022. The business continues to
progress with its clinical pipeline and trials, however the quoted
share price has fallen on the back of limited trading volumes. We
continue to believe that there will be long-term appreciation in
the share price, as key milestones continue to be achieved.
Liquidity investments
The Ventures Share pool holds a non-qualifying investment in
Downing Strategic Micro-Cap Investment Trust plc ("DSM"). This
decreased in value by GBP106,000 over the period, broadly in line
with market conditions, although has seen some recovery since the
period end.
Downing Micro-Cap Growth Fund, in which the share pool also had
a small holding, completed the task of returning funds to
shareholders as part of its wind up, producing a realised gain of
GBP7,000 in the period.
Outlook
A significant proportion of the value of the Healthcare
portfolio is in companies that have floated after our initial VCT
investment. The share price of small, quoted companies can often
tend to be disproportionately affected in weaker markets. Whilst
Genincode is performing behind plan, we believe the other quoted
companies in the Healthcare portfolio are making good progress,
which has not been reflected in their share prices.
Over the remainder of the year, we will continue to focus on
supporting the existing companies in the Healthcare Portfolio,
whilst also looking to further add to this portfolio in deploying
existing and new fundraising proceeds. The healthcare sector
continues to provide a good level of dealflow, and we hope that new
fundraising will allow us to take advantage of some of the best
opportunities which present themselves.
Downing LLP
Review of Investments -- Healthcare Share Pool
The following investments were held at 30 September 2022:
Cost Valuation
as at 30 as at 30 Valuation
September September movement % of
2022 2022 in period portfolio
Portfolio of investments GBP'000 GBP'000 GBP'000
Arecor Therapeutics plc^ 1,533 2,894 (1,292) 17.6%
----------------------------------------- ---------- ---------- ---------- ----------
Adaptix Limited 1,056 1,843 - 11.2%
----------------------------------------- ---------- ---------- ---------- ----------
Open Bionics Limited 1,000 1,630 251 9.9%
----------------------------------------- ---------- ---------- ---------- ----------
FVRVS Limited (t/a Fundamental VR) 1,305 1,559 36 9.5%
----------------------------------------- ---------- ---------- ---------- ----------
GENinCode plc^ 1,202 1,082 (542) 6.6%
----------------------------------------- ---------- ---------- ---------- ----------
Congenica Limited 1,184 865 (350) 5.3%
----------------------------------------- ---------- ---------- ---------- ----------
Cambridge Respiratory Innovations
Limited 800 800 - 4.9%
----------------------------------------- ---------- ---------- ---------- ----------
Closed Loop Medicine Limited 650 650 - 4.0%
----------------------------------------- ---------- ---------- ---------- ----------
DiA Imaging Analysis Limited 415 568 139 3.5%
----------------------------------------- ---------- ---------- ---------- ----------
The Electrospinning Company Limited 478 544 - 3.3%
----------------------------------------- ---------- ---------- ---------- ----------
Invizius Limited 500 500 - 3.1%
----------------------------------------- ---------- ---------- ---------- ----------
MIP Diagnostics Limited 300 300 - 1.8%
----------------------------------------- ---------- ---------- ---------- ----------
Destiny Pharma plc^ 750 162 (67) 1.0%
----------------------------------------- ---------- ---------- ---------- ----------
Live Better With Limited 1,106 - - 0.0%
----------------------------------------- ---------- ---------- ---------- ----------
12,279 13,397 (1,825) 81.7%
----------------------------------------- ---------- ---------- ---------- ----------
Liquidity Investments
----------------------------------------- ---------- ---------- ---------- ----------
Downing Strategic Micro-Cap Investment
Trust plc*^ 729 385 (106) 2.4%
----------------------------------------- ---------- ---------- ---------- ----------
84.1%
----------------------------------------- ---------- ---------- ---------- ----------
Cash at bank and in hand 2,596 15.9%
----------------------------------------- ---------- ---------- ---------- ----------
Total investments 13,008 16,378 (1,931) 100.0%
----------------------------------------- ---------- ---------- ---------- ----------
*non-qualifying investment
^listed and traded on the London Stock Exchange
Investment movements for the period ended 30 September 2022
Cost
Additions GBP'000
FVRVS Limited (t/a Fundamental
VR) 805
------------------------------- -------
805
------------------------------- -------
Valuation Profit Realised
Cost at 01/04/21 Proceeds vs. cost gain
Disposals GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Future Health Works Limited
(t/a MyRecovery) 528 750 798 270 48
------------------------------- ------- ------------ -------- --------- --------
FVRVS Limited (t/a Fundamental
VR) 250 250 250 - -
------------------------------- ------- ------------ -------- --------- --------
Liquidity investments
------------------------------- ------- ------------ -------- --------- --------
MI Downing UK Micro-Cap Growth
Fund* 40 37 44 4 7
------------------------------- ------- ------------ -------- --------- --------
818 1,037 1,092 274 55
------------------------------- ------- ------------ -------- --------- --------
*non-qualifying investment
Investment Manager's Report DSO D Share Pool
Introduction
The process of realising the investments and returning funds to
Shareholders remains the focus of the DSO D Share pool, although
this has continued to be subject to significant delays.
Net Asset Value and results
The Net Asset Value ("NAV") per DSO D Share at 30 September
2022, stood at 2.6p.
Total Return stands at 104.6p per share compared to initial cost
to Shareholders, net of income tax relief, of 70.0p per Share. We
consider this to be a satisfactory performance when compared to the
initial NAV of 100p.
The loss on ordinary activities after taxation for the period
was GBP4,000, comprising a revenue gain of GBP23,000 and a capital
loss of GBP27,000.
We continue to experience delays in exiting from the DSO D Share
pool's investments in Pearce and Saunders and Pearce and Saunders
DevCo Limited. We are working on plans to extract the remaining
values for the companies.
Ventures investments
As at 30 September 2022, the DSO D Share Pool held two ventures
investments with a total value of GBP16,000.
There have been no movements in the portfolio during the period,
as we continue to push to exit the final investments at the highest
possible proceeds for investors.
Portfolio valuation
During the year, the carrying value of the portfolio of
investments held by the DSO D Share pool was decreased by
GBP27,000.
Pearce and Saunders Limited made a final distribution of
GBP24,000 of interest to the Company in the period, and now has no
further value to distribute, resulting in a reduction in the
investment value of GBP27,000.
Pearce and Saunders DevCo Limited has a residual balance of
GBP16,000, anticipated to be recovered in the final exit process
hoped for next year.
Outlook
The focus for the DSO D Share pool continues to be on realising
the remaining investments. A final distribution will be paid once
the remaining realisations have taken place.
Foresight Group LLP
Review of investments - DSO D Share Pool
The following investments were held at 30 September 2022:
Cost Valuation
as at 30 as at 30 Valuation
September September movement % of
2022 2022 in period portfolio
Portfolio of investments GBP'000 GBP'000 GBP'000
Pearce and Saunders Limited 255 - (27) 0.0%
------------------------------ ---------- ---------- ---------- ----------
Pearce and Saunders DevCo
Limited* 19 16 - 15.5%
------------------------------ ---------- ---------- ---------- ----------
274 16 (27) 15.5%
------------------------------ ---------- ---------- ---------- ----------
Cash at bank and in hand 87 84.5%
------------------------------ ---------- ---------- ---------- ----------
Total investments 103 100.0%
------------------------------ ---------- ---------- ---------- ----------
* non-qualifying investment
There were no investment disposals during the period.
Investment Manager's Report - DP67 Share Pool
Introduction
The process of realising the investments and returning funds to
DP67 Shareholders remains the focus for this Share pool, although
this continues to be subject to substantial delays, with the
remaining assets all in the hospitality sector.
Net Asset Value and results
The Net Asset Value ("NAV") per DP67 Share at 30 September 2022
stood at 24.4p, a decrease of 2.4p over the period. Total Return
stands at 92.2p per DP67 Share, compared to initial cost to
Shareholders, net of income tax relief, of 70.0p per Share.
The loss on ordinary activities after taxation for the period
was GBP268,000, comprising a revenue loss of GBP156,000 and a
capital loss of GBP112,000.
We continue to try to work towards achieving optimal proceeds
for shareholders from the remnants of the portfolio, in what
continues to be a challenging environment in the hospitality
sector.
Ventures investments
As at 30 September 2022, the DP67 Share pool held a portfolio of
five investments, with a total value of GBP1.8 million.
Portfolio activity
There were no realisations during the period.
Portfolio valuation
The DP67 portfolio decreased in value by a total of GBP107,000
during the period. This was wholly attributable to Fenkle Street
LLP, which has been adjusted to reflect the anticipated proceeds
from the pending sale, along with Gatewales Limited. As part of the
terms agreed, Fenkle Street will make a contribution to the
remedial fire stopping improvement works required, which is
reflected in the decrease in value.
Cadbury House Holdings is now actively marketing its hotel, and
the value reflects the third-party valuation carried out for that
process. It remains unchanged since the year end. We hope to
achieve an exit by mid-2023.
Outlook
We are hopeful that the current plans will deliver exits from
each of the remaining investments in the reasonably near future,
now that the impact of the coronavirus pandemic on these assets is
mostly behind us. There are now, of course, new challenges,
including increasing inflation and spiralling energy costs, so we
are keen to see transactions complete without undue delay.
Final dividends will be paid once the remaining realisations
have taken place.
Foresight Group LLP
Review of Investments -- DP67 Share PoolDP67
The following investments were held at 30 September 2022:
Valuation
movement % of
Cost Valuation in period portfolio
Portfolio of investments GBP'000 GBP'000 GBP'000
Cadbury House Holdings Limited 1,409 791 - 44.1%
------------------------------- ------- ---------- ---------- ----------
Fenkle Street LLP* 405 652 (107) 36.3%
------------------------------- ------- ---------- ---------- ----------
Gatewales Limited** 343 344 - 19.2%
------------------------------- ------- ---------- ---------- ----------
Yamuna Renewables Limited 400 - - 0.0%
------------------------------- ------- ---------- ---------- ----------
London City Shopping Centre
Limited* 99 - - 0.0%
------------------------------- ------- ---------- ---------- ----------
2,656 1,787 (107) 99.6%
------------------------------- ------- ---------- ---------- ----------
Cash at bank and in hand 8 0.4%
------------------------------- ------- ---------- ---------- ----------
Total investments 1,795 100.0%
------------------------------- ------- ---------- ---------- ----------
*non-qualifying investment
**partially qualifying investment
There were no investment disposals during the period.
Investment Manager's Report - AIM Share Pool
The AIM Share class raised a total of GBP2.7 million in its
initial fundraising, which closed in May 2022. The NAV stands at
99.0p at 30 September 2022.
Since the original launch, the world has changed significantly
with the start of the war in Ukraine, impending recession and poor
market sentiment resulting in the current deal flow of VCT
qualifying AIM fundraisers being at a low level.
However, the team continue to see all new qualifying secondary
and imminent IPOs and are using this time to perform enhanced due
diligence on potential investments. In the meantime, since the
period end, some of the funds have been invested in liquidity
assets, which include a yielding money market fund and a market
tracker.
We hope to report an increased level of activity in the Annual
Report.
Downing LLP
Unaudited Income Statement
for the six months ended 30 September 2022
Year
ended
Six months ended Six months ended 31 Mar
30 Sep 2022 30 Sep 2021 2022
Revenue Capital Total Revenue Capital Total Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Income 158 - 158 43 2 45 1,296
(Losses)/gains on
investments - (17) (17) - 7,244 7,244 6,599
--------------------------- ------- ------- ------- ------- ------- ------- -------
158 (17) 141 43 7,246 7,289 7,895
--------------------------- ------- ------- ------- ------- ------- ------- -------
Investment management
fees (168) (168) (336) (244) (244) (488) (1,062)
--------------------------- ------- ------- ------- ------- ------- ------- -------
Other expenses (512) - (512) (209) - (209) (409)
--------------------------- ------- ------- ------- ------- ------- ------- -------
(Loss)/profit on ordinary
activities before tax (522) (185) (707) (410) 7,002 6,592 6,424
--------------------------- ------- ------- ------- ------- ------- ------- -------
Tax on total comprehensive
income and ordinary
activities - - - - - - -
--------------------------- ------- ------- ------- ------- ------- ------- -------
(Loss)/profit attributable
to equity Shareholders,
being total comprehensive
income for the period (522) (185) (707) (410) 7,002 6,592 6,424
--------------------------- ------- ------- ------- ------- ------- ------- -------
Basic and diluted return
per share:
--------------------------- ------- ------- ------- ------- ------- ------- -------
Ventures Share (0.5p) 3.9p 3.4p (0.5p) 4.6p 4.1p 3.8p
--------------------------- ------- ------- ------- ------- ------- ------- -------
Healthcare Share (0.7p) (9.1p) (9.8p) (0.7p) 23.7p 23.0p 18.3p
--------------------------- ------- ------- ------- ------- ------- ------- -------
AIM Share (0.5p) (0.2p) (0.7p) n/a n/a n/a (2.3p)
--------------------------- ------- ------- ------- ------- ------- ------- -------
DSO D Share 0.3p (0.3p) (0.0p) (0.1p) 0.1p 0.0p 0.0p
--------------------------- ------- ------- ------- ------- ------- ------- -------
DP67 Share (1.4p) (1.0p) (2.4p) (0.2p) 1.3p 1.1p 8.3p
--------------------------- ------- ------- ------- ------- ------- ------- -------
A Statement of Total Recognised Gains and Losses has not been
prepared as all gains and losses are recognised in the Income
Statement as noted above.
Unaudited Income Statement
Analysed by Share pool
for the six months ended 30 September 2022
Year
ended
Six months ended Six months ended 31 Mar
30 Sep 2022 30 Sep 2021 2022
Revenue Capital Total Revenue Capital Total Total
Ventures Share pool GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Income 27 - 27 35 1 36 58
--------------------------- ------- ------- ------- ------- ------- ------- -------
Net gain on investments - 1,993 1,993 - 2,369 2,369 2,641
--------------------------- ------- ------- ------- ------- ------- ------- -------
27 1,993 2,020 35 2,370 2,405 2,699
--------------------------- ------- ------- ------- ------- ------- ------- -------
Investment management
fees (95) (95) (190) (152) (152) (304) (628)
--------------------------- ------- ------- ------- ------- ------- ------- -------
Other expenses (160) - (160) (136) - (136) (235)
--------------------------- ------- ------- ------- ------- ------- ------- -------
(Loss)/profit on ordinary
activities before
tax (228) 1,898 1,670 (253) 2,218 1,965 1,836
--------------------------- ------- ------- ------- ------- ------- ------- -------
Tax on total comprehensive
income and ordinary
activities - - - - - - -
--------------------------- ------- ------- ------- ------- ------- ------- -------
(Loss)/profit attributable
to equity Shareholders,
being total comprehensive
income for the period (228) 1,898 1,670 (253) 2,218 1,965 1,836
--------------------------- ------- ------- ------- ------- ------- ------- -------
Year
ended
Six months ended Six months ended 31 Mar
30 Sep 2022 30 Sep 2021 2022
Revenue Capital Total Revenue Capital Total Total
Healthcare Share pool GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Income - - - 8 1 9 21
--------------------------- ------- ------- ------- ------- ------- ------- -------
Net (loss)/gain on
investments - (1,876) (1,876) - 4,727 4,727 4,172
--------------------------- ------- ------- ------- ------- ------- ------- -------
- (1,876) (1,876) 8 4,728 4,736 4,193
--------------------------- ------- ------- ------- ------- ------- ------- -------
Investment management
fees (62) (62) (124) (82) (82) (164) (390)
--------------------------- ------- ------- ------- ------- ------- ------- -------
Other expenses (85) - (85) (58) - (58) (140)
--------------------------- ------- ------- ------- ------- ------- ------- -------
(Loss)/profit on ordinary
activities before
tax (147) (1,938) (2,085) (132) 4,646 4,514 3,663
--------------------------- ------- ------- ------- ------- ------- ------- -------
Tax on total comprehensive
income and ordinary
activities - - - - - - -
--------------------------- ------- ------- ------- ------- ------- ------- -------
(Loss)/profit attributable
to equity Shareholders,
being total comprehensive
income for the period (147) (1,938) (2,085) (132) 4,646 4,514 3,663
--------------------------- ------- ------- ------- ------- ------- ------- -------
Unaudited Income Statement
Analysed by Share pool
for the six months ended 30 September 2022
Year
ended
Six months ended Six months ended 31 Mar
30 Sep 2022 30 Sep 2021 2022
Revenue Capital Total Revenue Capital Total Total
AIM Share pool GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Income - - - n/a n/a n/a -
---------------------------- ------- ------- ------- ------- ------- ------- -------
Net gain on investments - - - n/a n/a n/a -
---------------------------- ------- ------- ------- ------- ------- ------- -------
- - - n/a n/a n/a -
---------------------------- ------- ------- ------- ------- ------- ------- -------
Investment management
fees (6) (6) (12) n/a n/a n/a (4)
---------------------------- ------- ------- ------- ------- ------- ------- -------
Other expenses (8) - (8) n/a n/a n/a (2)
---------------------------- ------- ------- ------- ------- ------- ------- -------
Loss on ordinary activities
before tax (14) (6) (20) n/a n/a n/a (6)
---------------------------- ------- ------- ------- ------- ------- ------- -------
Tax on total comprehensive
income and ordinary
activities - - - n/a n/a n/a -
---------------------------- ------- ------- ------- ------- ------- ------- -------
Loss attributable
to equity Shareholders,
being total comprehensive
income for the period (14) (6) (20) n/a n/a n/a (6)
---------------------------- ------- ------- ------- ------- ------- ------- -------
Unaudited Income Statement
Analysed by Share pool
for the six months ended 30 September 2022
Year
ended
Six months ended Six months ended 31 Mar
30 Sep 2022 30 Sep 2021 2022
Revenue Capital Total Revenue Capital Total Total
DSO D Share pool GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Income 24 - 24 - - - -
--------------------------- ------- ------- ------- ------- ------- ------- -------
Net gain/(loss) on
investments - (27) (27) - 10 10 19
--------------------------- ------- ------- ------- ------- ------- ------- -------
24 (27) (3) - 10 10 19
--------------------------- ------- ------- ------- ------- ------- ------- -------
Investment management
fees - - - (3) (3) (6) (12)
--------------------------- ------- ------- ------- ------- ------- ------- -------
Other expenses (1) - (1) (5) - (5) (10)
--------------------------- ------- ------- ------- ------- ------- ------- -------
(Loss)/profit on ordinary
activities before
tax 23 (27) (4) (8) 7 (1) (3)
--------------------------- ------- ------- ------- ------- ------- ------- -------
Tax on total comprehensive
income and ordinary
activities - - - - - - -
--------------------------- ------- ------- ------- ------- ------- ------- -------
(Loss)/profit attributable
to equity Shareholders,
being total comprehensive
income for the period 23 (27) (4) (8) 7 (1) (3)
--------------------------- ------- ------- ------- ------- ------- ------- -------
Unaudited Income Statement
Analysed by Share pool
for the six months ended 30 September 2022
Year
ended
Six months ended Six months ended 31 Mar
30 Sep 2022 30 Sep 2021 2022
Revenue Capital Total Revenue Capital Total Total
DP67 Share pool GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Income 107 - 107 10 - 10 1,217
--------------------------- ------- ------- ------- ------- ------- ------- -------
Net gain/(loss) on
investments - (107) (107) - (27) (27) (233)
--------------------------- ------- ------- ------- ------- ------- ------- -------
107 (107) - 10 (27) (17) 984
--------------------------- ------- ------- ------- ------- ------- ------- -------
Investment management
fees (5) (5) (10) (7) (7) (14) (28)
--------------------------- ------- ------- ------- ------- ------- ------- -------
Other expenses (258) - (258) (8) - (8) (22)
--------------------------- ------- ------- ------- ------- ------- ------- -------
(Loss)/profit on ordinary
activities before
tax (156) (112) (268) (5) (34) (39) 934
--------------------------- ------- ------- ------- ------- ------- ------- -------
Tax on total comprehensive
income and ordinary
activities - - - - - - -
--------------------------- ------- ------- ------- ------- ------- ------- -------
(Loss)/profit attributable
to equity Shareholders,
being total comprehensive
income for the period (156) (112) (268) (5) (34) (39) 934
--------------------------- ------- ------- ------- ------- ------- ------- -------
Unaudited Balance Sheet
as at 30 September 2022
As at 31
As at 30 September As at 30 September March
2022 2021 2022
GBP'000 GBP'000 GBP'000
Fixed assets
---------------------- ------------------ ------------------ --------
Investments (note
10) 48,181 48,900 49,141
---------------------- ------------------ ------------------ --------
Current assets
---------------------- ------------------ ------------------ --------
Debtors 1,729 393 4,317
---------------------- ------------------ ------------------ --------
Cash at bank and in
hand 10,290 4,964 8,384
---------------------- ------------------ ------------------ --------
12,019 5,357 12,701
---------------------- ------------------ ------------------ --------
Creditors: amounts
falling due within
one year (679) (644) (965)
---------------------- ------------------ ------------------ --------
Net current assets 11,340 4,713 11,736
---------------------- ------------------ ------------------ --------
Net assets 59,521 53,613 60,877
---------------------- ------------------ ------------------ --------
Capital and reserves
---------------------- ------------------ ------------------ --------
Called up Share
capital 120 103 113
---------------------- ------------------ ------------------ --------
Capital redemption
reserve 58 58 58
---------------------- ------------------ ------------------ --------
Special reserve 21,904 27,547 24,063
---------------------- ------------------ ------------------ --------
Share premium
account 31,726 20,919 29,284
---------------------- ------------------ ------------------ --------
Funds held in
respect of Shares
not yet allotted 8 194 7
---------------------- ------------------ ------------------ --------
Revaluation reserve 5,696 5,804 6,995
---------------------- ------------------ ------------------ --------
Capital reserve --
realised 3,943 3,166 3,769
---------------------- ------------------ ------------------ --------
Revenue reserve (3,934) (4,178) (3,412)
---------------------- ------------------ ------------------ --------
Total equity
Shareholders'
funds 59,521 53,613 60,877
---------------------- ------------------ ------------------ --------
Basic and diluted
Net Asset Value per
Share:
----------------------
Ventures Share 68.5p 68.5p 68.2p
---------------------- ------------------ ------------------ --------
Healthcare Share 71.7p 88.7p 84.4p
---------------------- ------------------ ------------------ --------
AIM Share 99.0p n/a 99.9p
---------------------- ------------------ ------------------ --------
DSO D Share 2.6p 10.2p 2.6p
---------------------- ------------------ ------------------ --------
DP67 Share 24.4p 19.5p 26.8p
---------------------- ------------------ ------------------ --------
Unaudited Balance Sheet
Analysed by Share pool
as at 30 September 2022
As at 31
As at 30 September As at 30 September March
2022 2021 2022
Ventures Share pool GBP'000 GBP'000 GBP'000
Fixed assets
------------------------
Investments 32,596 30,830 31,259
------------------------ ------------------ ------------------ --------
Current assets
------------------------ ------------------ ------------------ --------
Debtors 523 198 1,801
------------------------ ------------------ ------------------ --------
Cash at bank and in
hand 4,910 2,517 4,321
------------------------ ------------------ ------------------ --------
5,433 2,715 6,122
------------------------ ------------------ ------------------ --------
Creditors: amounts
falling due within
one year (288) (404) (490)
------------------------ ------------------ ------------------ --------
Net current assets 5,145 2,311 5,632
------------------------ ------------------ ------------------ --------
Net assets 37,741 33,141 36,891
------------------------ ------------------ ------------------ --------
Capital and reserves
------------------------ ------------------ ------------------ --------
Called up share
capital 69 60 65
------------------------ ------------------ ------------------ --------
Capital redemption
reserve 58 58 58
------------------------ ------------------ ------------------ --------
Special reserve 15,012 18,997 16,291
------------------------ ------------------ ------------------ --------
Share premium account 19,901 14,551 18,657
------------------------ ------------------ ------------------ --------
Funds held in respect
of shares not yet
allotted 1 189 2
------------------------ ------------------ ------------------ --------
Revaluation reserve 4,443 1,237 3,457
------------------------ ------------------ ------------------ --------
Capital reserve --
realised 1,552 878 1,428
------------------------ ------------------ ------------------ --------
Revenue reserve (3,295) (2,829) (3,067)
------------------------ ------------------ ------------------ --------
Total equity
Shareholders' funds 37,741 33,141 36,891
------------------------ ------------------ ------------------ --------
Unaudited Balance Sheet (continued)
Analysed by Share pool
as at 30 September 2022
As at 31
As at 30 September As at 30 September March
2022 2021 2022
Healthcare Share
pool GBP'000 GBP'000 GBP'000
--------------------
Fixed assets
-------------------- ------------------ ------------------- --------
Investments 13,782 15,350 15,945
-------------------- ------------------ ------------------- --------
Current assets
-------------------- ------------------ ------------------- --------
Debtors 10 194 633
-------------------- ------------------ ------------------- --------
Cash at bank and
in hand 2,596 2,137 2,483
-------------------- ------------------ ------------------- --------
2,606 2,331 3,116
-------------------- ------------------ ------------------- --------
Creditors: amounts
falling due
within one year (212) (187) (310)
-------------------- ------------------ ------------------- --------
Net current assets 2,394 2,144 2,806
-------------------- ------------------ ------------------- --------
Net assets 16,176 17,494 18,751
-------------------- ------------------ ------------------- --------
Capital and
reserves
-------------------- ------------------ ------------------- --------
Called up share
capital 29 24 27
-------------------- ------------------ ------------------- --------
Special reserve 6,877 7,987 7,752
-------------------- ------------------ ------------------- --------
Share premium
account 9,132 6,368 8,594
-------------------- ------------------ ------------------- --------
Funds held in
respect of shares
not yet allotted 7 5 5
-------------------- ------------------ ------------------- --------
Revaluation
reserve 1,881 4,587 4,031
-------------------- ------------------ ------------------- --------
Capital reserve --
realised (18) (74) (73)
-------------------- ------------------ ------------------- --------
Revenue reserve (1,732) (1,403) (1,585)
-------------------- ------------------ ------------------- --------
Total equity
Shareholders'
funds 16,176 17,494 18,751
-------------------- ------------------ ------------------- --------
AIM Share pool
--------------------
Fixed assets
-------------------- ------------------ ------------------ --------
Investments - n/a -
-------------------- ------------------ ------------------ --------
Current assets
-------------------- ------------------ ------------------ --------
Debtors 2 n/a 604
-------------------- ------------------ ------------------ --------
Cash at bank and
in hand 2,689 n/a 1,446
-------------------- ------------------ ------------------ --------
2,691 n/a 2,050
-------------------- ------------------ ------------------ --------
Creditors: amounts
falling due
within one year (21) n/a (21)
-------------------- ------------------ ------------------ --------
Net current assets 2,670 n/a 2,029
-------------------- ------------------ ------------------ --------
Net assets 2,670 n/a 2,029
-------------------- ------------------ ------------------ --------
Capital and
reserves
-------------------- ------------------ ------------------ --------
Called up share
capital 3 n/a 2
-------------------- ------------------ ------------------ --------
Special reserve - n/a (2)
-------------------- ------------------ ------------------ --------
Share premium
account (8) n/a 2,033
-------------------- ------------------ ------------------ --------
Funds held in
respect of shares
not yet allotted 2,693 n/a -
-------------------- ------------------ ------------------ --------
Revaluation
reserve - n/a -
-------------------- ------------------ ------------------ --------
Revenue reserve (18) n/a (4)
-------------------- ------------------ ------------------ --------
Total equity
Shareholders'
funds 2,670 n/a 2,029
-------------------- ------------------ ------------------ --------
Unaudited Balance Sheet (continued)
Analysed by Share pool
as at 30 September 2022
As at 31
As at 30 September As at 30 September March
2022 2021 2022
DSO D Share pool GBP'000 GBP'000 GBP'000
------------------------
Fixed assets
------------------------ ------------------ ------------------ --------
Investments 16 455 43
------------------------ ------------------ ------------------ --------
Current assets
------------------------ ------------------ ------------------ --------
Debtors 112 65 61
------------------------ ------------------ ------------------ --------
Cash at bank and in
hand 87 300 124
------------------------ ------------------ ------------------ --------
199 365 185
------------------------ ------------------ ------------------ --------
Creditors: amounts
falling due within
one year (11) (20) (20)
------------------------ ------------------ ------------------ --------
Net current assets 188 345 165
------------------------ ------------------ ------------------ --------
Net assets 204 800 208
------------------------ ------------------ ------------------ --------
Capital and reserves
------------------------ ------------------ ------------------ --------
Called up share
capital 8 8 8
------------------------ ------------------ ------------------ --------
Special reserve 423 963 423
------------------------ ------------------ ------------------ --------
Revaluation reserve (258) (128) (231)
------------------------ ------------------ ------------------ --------
Capital reserve --
realised 22 (37) 22
------------------------ ------------------ ------------------ --------
Revenue reserve 9 (6) (14)
------------------------ ------------------ ------------------ --------
Total equity
Shareholders' funds 204 800 208
------------------------ ------------------ ------------------ --------
DP67 Share pool
------------------------
Fixed assets
------------------------ ------------------ ------------------ --------
Investments 1,787 2,265 1,894
------------------------ ------------------ ------------------ --------
Current assets
------------------------ ------------------ ------------------ --------
Debtors 1,082 1 1,218
------------------------ ------------------ ------------------ --------
Cash at bank and in
hand 8 10 10
------------------------ ------------------ ------------------ --------
1,090 11 1,228
------------------------ ------------------ ------------------ --------
Creditors: amounts
falling due within
one year (147) (98) (124)
------------------------ ------------------ ------------------ --------
Net current assets 943 (87) 1,104
------------------------ ------------------ ------------------ --------
Net assets 2,730 2,178 2,998
------------------------ ------------------ ------------------ --------
Capital and reserves
------------------------ ------------------ ------------------ --------
Called up share
capital 11 11 11
------------------------ ------------------ ------------------ --------
Special reserve (400) (400) (400)
------------------------ ------------------ ------------------ --------
Revaluation reserve (370) 108 (263)
------------------------ ------------------ ------------------ --------
Capital reserve --
realised 2,387 2,399 2,392
------------------------ ------------------ ------------------ --------
Revenue reserve 1,102 60 1,258
------------------------ ------------------ ------------------ --------
Total equity
Shareholders' funds 2,730 2,178 2,998
------------------------ ------------------ ------------------ --------
Statement of Changes in Equity
for the six months ended 30 September 2022
Funds
held
Called in respect
up Capital Share of Shares Capital
Share Redemp-tion Special premium not yet Reval-uation reserve Revenue
capital reserve reserve account allotted Reserve - realised reserve Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
---------------------- -----------
At 31 March 2021 102 58 29,417 20,010 241 (1,143) 3,132 (3,768) 48,049
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Total comprehensive
income - - - - - 6,335 (267) 356 6,424
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Transfer between
reserves* - - (5,159) - - 1,803 3,356 - -
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Unallotted Shares - - - - (234) - - - (234)
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Transactions with
owners
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Dividend paid - - - - - - (2,452) - (2,452)
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Purchase of own
shares - - (195) - - - - - (195)
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Issue of shares 11 - - 9,501 - - - - 9,512
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Share issue costs - - - (227) - - - - (227)
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
At 31 March 2022 113 58 24,063 29,284 7 6,995 3,769 (3,412) 60,877
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Total comprehensive
income - - - - - 44 (229) (522) (707)
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Transfer between
reserves* - - (1,365) - (1,343) 2,708 - -
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Unallotted Shares - - - - 1 - - - 1
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Transactions with
owners
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Dividend paid - - - - - - (2,305) - (2,305)
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Purchase of own
shares - - (794) - - - - (794)
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Issue of shares 7 - - 2,499 - - - - 2,506
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
Share issue costs - - - (57) - - - - (57)
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
At 30 Sept 2022 120 58 21,904 31,726 8 5,696 3,943 (3,934) 59,521
---------------------- -------- ------------ -------- -------- ----------- ------------ ----------- -------- -------
* A transfer of GBP1,343,000 (2022: GBP1,803,000) representing
previously recognised realised gains and losses on disposal of
investments during the period has been made between the Revaluation
Reserve and the Capital reserve - realised. A transfer of
GBP1,365,000 (2022: GBP5,159,000) representing the total of:
realised losses on the disposal of investments, cumulative
impairment losses, capital expenses and capital dividends in the
period, has been made between the Capital Reserve - realised and
the Special reserve.
Unaudited Statement of Cash Flows
for the six months ended 30 September 2022
DSO D DP67 Ventures Healthcare
Share Share Share Share AIM Share
pool pool pool pool pool Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Cash flows from operating activities
------------------------------------- ------- ------- -------- ---------- --------- -------
(Loss)/return on ordinary activities
before taxation (4) (268) 1,670 (2,085) (20) (707)
------------------------------------- ------- ------- -------- ---------- --------- -------
Losses/(gains) on investments 27 107 (1,993) 1,876 - 17
------------------------------------- ------- ------- -------- ---------- --------- -------
Increase/(decrease) in creditors (9) 23 (202) (98) - (286)
------------------------------------- ------- ------- -------- ---------- --------- -------
(Increase)/decrease in debtors (51) 136 1,278 623 602 2,588
------------------------------------- ------- ------- -------- ---------- --------- -------
Net cash (outflow)/inflow from
operating activities (37) (2) 753 316 582 1,612
------------------------------------- ------- ------- -------- ---------- --------- -------
Corporation tax paid - - - - - -
------------------------------------- ------- ------- -------- ---------- --------- -------
Net cash generated from operating
activities - - 753 316 582 1,612
------------------------------------- ------- ------- -------- ---------- --------- -------
Cash flow from investing activities
------------------------------------- ------- ------- -------- ---------- --------- -------
Purchase of investments - - (3,457) (805) - (4,262)
------------------------------------- ------- ------- -------- ---------- --------- -------
Proceeds from disposal of investments - - 4,113 1,092 - 5,205
------------------------------------- ------- ------- -------- ---------- --------- -------
Net cash inflow from investing
activities - - 656 287 - 943
------------------------------------- ------- ------- -------- ---------- --------- -------
Net cash (outflow)/inflow before
financing (37) (2) 1,409 603 582 2,555
------------------------------------- ------- ------- -------- ---------- --------- -------
Cash flows from financing activities
------------------------------------- ------- ------- -------- ---------- --------- -------
Issue of share capital - - (551) (243) - (794)
------------------------------------- ------- ------- -------- ---------- --------- -------
Issue of share capital - - 1,276 552 678 2,506
------------------------------------- ------- ------- -------- ---------- --------- -------
Cost of issue of share capital - - (28) (12) (17) (57)
------------------------------------- ------- ------- -------- ---------- --------- -------
Funds held in respect of shares
not yet allotted - - (1) 2 - 1
------------------------------------- ------- ------- -------- ---------- --------- -------
Equity dividends paid - - (1,516) (789) - (2,305)
------------------------------------- ------- ------- -------- ---------- --------- -------
Net cash outflow/(inflow) from
financing activities (37) (2) (820) (490) 661 (649)
------------------------------------- ------- ------- -------- ---------- --------- -------
Net change in cash (37) (2) 589 113 1,243 1,906
------------------------------------- ------- ------- -------- ---------- --------- -------
Cash and cash equivalents at
start of the year 124 10 4,321 2,483 1,446 8,384
------------------------------------- ------- ------- -------- ---------- --------- -------
Cash and cash equivalents at
end of the year 87 8 4,910 2,596 2,689 10,290
------------------------------------- ------- ------- -------- ---------- --------- -------
Cash and cash equivalents comprise
------------------------------------- ------- ------- -------- ---------- --------- -------
Cash at bank and in hand 87 8 4,910 2,596 2,689 10,290
------------------------------------- ------- ------- -------- ---------- --------- -------
Total cash and cash equivalents 87 8 4,910 2,596 2,689 10,290
------------------------------------- ------- ------- -------- ---------- --------- -------
Unaudited Statement of Cash Flows
for the six months ended 30 September 2021
DSO D DP67 Ventures Healthcare
Share Share Share Share
pool pool pool pool Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Cash flows from operating activities
----------------------------------------- ------- ------- -------- ---------- -------
(Loss)/return on ordinary activities
before taxation (1) 114 1,965 4,514 6,592
----------------------------------------- ------- ------- -------- ---------- -------
Gains on investments (10) (138) (2,369) (4,728) (7,245)
----------------------------------------- ------- ------- -------- ---------- -------
Increase in creditors 3 24 164 88 279
----------------------------------------- ------- ------- -------- ---------- -------
(Increase)/decrease in debtors (36) - 269 59 292
----------------------------------------- ------- ------- -------- ---------- -------
Net cash (outflow)/inflow from operating
activities (44) - 29 (67) (82)
----------------------------------------- ------- ------- -------- ---------- -------
Corporation tax paid - - - - -
----------------------------------------- ------- ------- -------- ---------- -------
Net cash generated from operating
activities (44) - 29 (67) (82)
----------------------------------------- ------- ------- -------- ---------- -------
Cash flow from investing activities
----------------------------------------- ------- ------- -------- ---------- -------
Purchase of investments - - (547) (3,614) (4,161)
----------------------------------------- ------- ------- -------- ---------- -------
Proceeds from disposal of investments - - 719 2,529 3,248
----------------------------------------- ------- ------- -------- ---------- -------
Net cash inflow/(outflow) from investing
activities - - 172 (1,085) (913)
----------------------------------------- ------- ------- -------- ---------- -------
Net cash (outflow)/inflow before
financing (44) - 201 (1,152) (995)
----------------------------------------- ------- ------- -------- ---------- -------
Cash flows from financing activities
----------------------------------------- ------- ------- -------- ---------- -------
Issue of share capital - - (11) (14) (25)
----------------------------------------- ------- ------- -------- ---------- -------
Issue of share capital - - 556 378 934
----------------------------------------- ------- ------- -------- ---------- -------
Cost of issue of share capital - - (14) (10) (24)
----------------------------------------- ------- ------- -------- ---------- -------
Funds held in respect of shares not
yet allotted - - (33) (14) (47)
----------------------------------------- ------- ------- -------- ---------- -------
Equity dividends paid - - (1,323) (542) (1,865)
----------------------------------------- ------- ------- -------- ---------- -------
Net cash outflow from financing
activities - - (825) (202) (1,027)
----------------------------------------- ------- ------- -------- ---------- -------
Net change in cash (44) - (624) (1,354) (2,022)
----------------------------------------- ------- ------- -------- ---------- -------
Cash and cash equivalents at start
of the year 344 10 3,141 3,491 6,986
----------------------------------------- ------- ------- -------- ---------- -------
Cash and cash equivalents at end
of the year 300 10 2,517 2,137 4,964
----------------------------------------- ------- ------- -------- ---------- -------
Cash and cash equivalents comprise
----------------------------------------- ------- ------- -------- ---------- -------
Cash at bank and in hand 300 10 2,517 2,137 4,964
----------------------------------------- ------- ------- -------- ---------- -------
Notes
1. General Information
Thames Ventures VCT 2 plc ("the Company") is a Venture Capital
Trust established under the legislation introduced in the Finance
Act 1995 and is domiciled in the United Kingdom and incorporated in
England and Wales.
2. Basis of accounting
The unaudited half-yearly financial results cover the six months
to 30 September 2022 and have been prepared in accordance with the
accounting policies set out in the statutory accounts for the year
ended 31 March 2022, which were prepared in accordance with the
Financial Reporting Standard 102 ("FRS 102") and the Statement of
Recommended Practice "Financial Statements of Investment Trust
Companies" issued in July 2022 ("SORP").
3. The Company has only one class of business and derives its
income from investments made in shares, securities and bank
deposits.
4. The comparative figures are in respect of the six months
ended 30 September 2021 and the year ended 31 March 2022
respectively.
5. Net Asset Value per share at the period end has been
calculated on the number of shares in issue at the period end as
follows:
Ventures Shares* 55,133,116
Healthcare Shares* 22,547,213
AIM Shares 2,695,803
DSO D Shares 7,867,247
DP67 Shares 11,192,136
*Excludes Management Shares
6. Return per share for the period has been calculated on the
average number of shares in issue in the period as follows:
Ventures Shares* 49,059,630
Healthcare Shares* 21,154,962
AIM Shares 2,640,965
DSO D Shares 7,867,247
DP67 Shares 11,192,136
*Excludes Management Shares
7. The unaudited financial statements set out herein do not
constitute statutory accounts within the meaning of Section 434 of
the Companies Act 2006 and have not been delivered to the Registrar
of Companies.
8. Dividends
Six months ended 30 September 2022
Pence per Revenue Capital Total
Share GBP'000 GBP'000 GBP'000
Ventures Shares
---------------------- --------- -------- -------- --------
Paid - 1,516 1,516
---------------------- --------- -------- -------- --------
Final (year ended
31 March 2022) 2.75 - 1,516 1,516
---------------------- --------- -------- -------- --------
Healthcare Shares
---------------------- --------- -------- -------- --------
Paid - 789 789
---------------------- --------- -------- -------- --------
Final (year ended
31 March 2022) 3.50 - 789 789
---------------------- --------- -------- -------- --------
9. Reserves
31 Mar
30 Sep 2022 30 Sep 2021 2022
GBP'000 GBP'000 GBP'000
---------------------------------------
Capital redemption reserve 58 58 58
--------------------------------------- ----------- ----------- -------
Special reserve 21,904 27,547 24,063
--------------------------------------- ----------- ----------- -------
Share premium account 31,726 20,919 29,284
--------------------------------------- ----------- ----------- -------
Revaluation reserve 5,696 5,804 6,995
--------------------------------------- ----------- ----------- -------
Capital reserve -- realised 3,943 3,166 3,769
--------------------------------------- ----------- ----------- -------
Revenue reserve (3,934) (4,178) (3,412)
--------------------------------------- ----------- ----------- -------
Funds held in respect of shares not yet
allotted 8 194 7
--------------------------------------- ----------- ----------- -------
59,401 53,510 60,764
--------------------------------------- ----------- ----------- -------
The Revenue reserve, Special reserve and Capital reserve -
realised are distributable reserves and are reduced by revaluation
losses of GBP9.8 million. Distributable reserves at 30 September
2022 were GBP13.1 million.
10. Fixed asset -- investments
Liquidity Quoted VC Unquoted
investments investments VC investments Total
GBP'000 GBP'000 GBP'000 GBP'000
Opening cost at 1 April 2022 5,161 4,403 40,146 49,710
Unrealised (losses)/gains at
1 April 2022 (1,642) 2,930 5,802 7,090
------------------------------ ------- ------------ --------------- -------
Unrealised foreign exchange
losses at 1 April 2022 - - (95) (95)
------------------------------ ------- ------------ --------------- -------
Impairment losses at 1 April
2022 - - (7,564) (7,564)
------------------------------ ------- ------------ --------------- -------
Opening fair value at 1 April
2022 3,519 7,333 38,289 49,141
------------------------------ ------- ------------ --------------- -------
Movements in the year:
------------------------------ ------- ------------ --------------- -------
Purchased at cost - - 4,262 4,262
------------------------------ ------- ------------ --------------- -------
Disposals - proceeds (183) - (5,022) (5,205)
------------------------------ ------- ------------ --------------- -------
- realised gains on
disposals 30 - (91) (61)
------------------------------ ------- ------------ --------------- -------
Unrealised foreign exchange
gains - - 1,051 1,051
------------------------------ ------- ------------ --------------- -------
Unrealised (losses)/gains in
the Income Statement (724) (2,298) 2,015 (1,007)
------------------------------ ------- ------------ --------------- -------
Closing value at 30 Sept 2022 2,642 5,035 40,504 48,181
------------------------------ ------- ------------ --------------- -------
Closing cost at 30 Sept 2022 4,998 4,403 40,648 50,049
------------------------------ ------- ------------ --------------- -------
Unrealised (losses)/gains at
30 Sept 2022 (2,356) 632 6,464 4,740
------------------------------ ------- ------------ --------------- -------
Unrealised foreign exchange
gains at 30 Sept 2022 - - 956 956
------------------------------ ------- ------------ --------------- -------
Impairment losses at 30 Sept
2022 - - (7,564) (7,564)
------------------------------ ------- ------------ --------------- -------
Closing value at 30 Sept 2022 2,642 5,035 40,504 48,181
------------------------------ ------- ------------ --------------- -------
The fair value of investments is determined using the detailed
accounting policy as shown in the audited financial statements for
the year ended 31 March 2022. The Company has categorised its
financial instruments using the fair value hierarchy as
follows:
Level 1 Reflects financial instruments quoted in an active market (quoted companies, investment funds and fixed interest bonds);
Level 2 Reflects financial instruments that have prices that are observable either directly or indirectly; and
Level 3 Reflects financial instruments that use valuation techniques that are not based on observable market data (investments in unquoted shares and loan note investments).
Level Level Level 30 Sept Level Level Level 31 Mar
1 2 3 2022 1 2 3 2022
-------------- ------- ------- ------- ------- ------- ------- ------- -------
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
-------------- ------- ------- ------- ------- ------- ------- ------- -------
Liquidity
investments 2,642 - - 2,642 3,519 - - 3,519
-------------- ------- ------- ------- ------- ------- ------- ------- -------
Quoted equity 5,035 - - 5,035 7,333 - - 7,333
-------------- ------- ------- ------- ------- ------- ------- ------- -------
Unquoted loan
notes - - 2,194 2,194 - - 3,250 3,250
-------------- ------- ------- ------- ------- ------- ------- ------- -------
Unquoted
equity - - 38,310 38,310 - - 35,039 35,039
-------------- ------- ------- ------- ------- ------- ------- ------- -------
7,677 - 40,504 48,181 10,852 - 38,289 49,141
-------------- ------- ------- ------- ------- ------- ------- ------- -------
11. Risk and uncertainties
Under the Disclosure and Transparency Directive, the Board is
required in the Company's half-year results to report on the
principal risks and uncertainties facing the Company over the
remainder of the financial year.
The Board has concluded that the key risks facing the Company
over the remainder of the financial period are as follows:
(i) compliance risk of failure to maintain approval as a VCT;
(ii) market, liquidity and counterparty risk associated with Public Equity investments; and
(iii) investment risk associated with investing in small and immature businesses.
The Company's compliance with the VCT regulations is continually
monitored by the Manager, who reports regularly to the Board on the
current position. The Company also retains Philip Hare &
Associates LLP ("Philip Hare") to provide regular reviews and
advice in this area. Philip Hare has confirmed that all relevant
tests have been complied with for the period under review. The
Board considers that this approach reduces the risk of a breach of
the VCT regulations.
With this approach, the Board believes that these risks are
reduced.
In order to make VCT qualifying investments, the Company has to
invest in small businesses which are often immature. It also has a
limited period in which it must invest the majority of its funds
into VCT qualifying investments. The Manager follows a rigorous
process in vetting and carefully structuring new investments,
including taking a charge over the assets of the business wherever
possible and, after an investment is made, closely monitoring the
business.
12. Going concern
The Directors have reviewed the Company's financial resources at
the period end and conclude that the Company is well placed to
manage its business risks.
The Board confirms that it is satisfied that the Company has
adequate resources to continue in business for the foreseeable
future. For this reason, the Board believes that the Company
continues to be a going concern and that it is appropriate to apply
the going concern basis in preparing the financial statements.
13. The Directors confirm that, to the best of their knowledge, the Half-Yearly Report has been prepared in accordance with the "Statement: Half-Yearly Financial Reports" issued by the UK Accounting Standards Board as well as in accordance with FRS 104 Interim Financial Reporting, and the half-yearly financial report includes a fair review of the information required by:
a. DTR 4.2.7R of the Disclosure and Transparency Rules, being an
indication of important events that have occurred during the first
six months of the financial year and their impact on the condensed
set of financial statements, and a description of the principal
risks and uncertainties for the remaining six months of the year;
and
b. DTR 4.2.8R of the Disclosure and Transparency Rules, being
related party transactions that have taken place in the first six
months of the current financial year and that have materially
affected the financial position or performance of the entity during
that period, and any changes in the related party transactions
described in the last annual report that could do so.
14. Copies of the Half-Yearly Report will be sent to Shareholders shortly. Further copies can be obtained from the Company's registered office or downloaded from https://www.foresightgroup.eu/products/thames-ventures-vct-2-plc https://www.globenewswire.com/Tracker?data=RRmIgEk9maTb3Hb0S2homPUCbQP6wLBSN_n7v5zi9oke1soxrP3JtqXIa6yD1kiRqnxKS8iSGTzmHWSW2ri-LByGpkrcyRLWbyi93Kg9LZU22VM-_L-VLiD7BPzqbW8O
(END) Dow Jones Newswires
December 22, 2022 12:08 ET (17:08 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Thames Ventures Vct 2 (LSE:D467)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Thames Ventures Vct 2 (LSE:D467)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
